Sirolimus as a promising candidate for COVID19
December 16, 2020 / Cutting edges
Rising expectations to a novel treatment against Covid-19 infection, many researchers suggested the potential use of sirolimus. Sirolimus inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro- inflammatory cytokines such as IL-2 and IL-6. Therefore, the use of sirolimus may be useful to inhibit viral particle synthesis, cytokine storms, and thus, contributes to fight the disease. As sirolimus controls the host factors and not viral machinery, it is unlikely that the virus becomes resistant to sirolimus. Additionally, the inhibitory effect of sirolimus on cell proliferation may aid in reducing viral replication.
References
- An Update on Current Therapeutic Drugs Treating COVID-19.
Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, Poiani GJ, Amorosa L, Brunetti L, Kong AN.
Curr Pharmacol Rep. 2020 May 11:1-15. doi: 10.1007/s40495-020-00216-7. - Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F.
Cell Discov. 2020 Mar 16;6:14. doi: 10.1038/s41421-020-0153-3. eCollection 2020. - Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.
Husain A, Byrareddy SN.
Chem Biol Interact. 2020 Nov 1;331:109282. doi: 10.1016/j.cbi.2020.109282. Epub 2020 Oct 6.